CN107669727B - Chest-relaxing pulse controlled-release dropping pill for enhancing coronary vasodilation effect of chest-relaxing dropping pill and preparation method thereof - Google Patents
Chest-relaxing pulse controlled-release dropping pill for enhancing coronary vasodilation effect of chest-relaxing dropping pill and preparation method thereof Download PDFInfo
- Publication number
- CN107669727B CN107669727B CN201711147105.XA CN201711147105A CN107669727B CN 107669727 B CN107669727 B CN 107669727B CN 201711147105 A CN201711147105 A CN 201711147105A CN 107669727 B CN107669727 B CN 107669727B
- Authority
- CN
- China
- Prior art keywords
- pill
- chest
- medicinal material
- relaxing
- micro powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006187 pill Substances 0.000 title claims abstract description 92
- 238000013270 controlled release Methods 0.000 title claims abstract description 59
- 230000000694 effects Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 12
- 230000024883 vasodilation Effects 0.000 title claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 86
- 239000000463 material Substances 0.000 claims abstract description 69
- 238000000576 coating method Methods 0.000 claims abstract description 45
- 239000011248 coating agent Substances 0.000 claims abstract description 42
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 31
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 31
- 239000000284 extract Substances 0.000 claims abstract description 30
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 29
- 230000008961 swelling Effects 0.000 claims abstract description 19
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 17
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 17
- 238000002156 mixing Methods 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 239000000758 substrate Substances 0.000 claims abstract description 8
- 229940119485 safflower extract Drugs 0.000 claims abstract description 3
- 239000002245 particle Substances 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 238000001914 filtration Methods 0.000 claims description 19
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 14
- 241000180649 Panax notoginseng Species 0.000 claims description 14
- 241000628997 Flos Species 0.000 claims description 12
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 12
- 239000001856 Ethyl cellulose Substances 0.000 claims description 11
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 11
- 229920001249 ethyl cellulose Polymers 0.000 claims description 11
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 11
- 238000010298 pulverizing process Methods 0.000 claims description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 9
- 239000011159 matrix material Substances 0.000 claims description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- 229920002678 cellulose Polymers 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 8
- 230000001186 cumulative effect Effects 0.000 claims description 8
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- 239000006185 dispersion Substances 0.000 claims description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 6
- 239000008117 stearic acid Substances 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- 239000004925 Acrylic resin Substances 0.000 claims description 4
- 229920000178 Acrylic resin Polymers 0.000 claims description 4
- 235000021357 Behenic acid Nutrition 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 235000013871 bee wax Nutrition 0.000 claims description 4
- 239000012166 beeswax Substances 0.000 claims description 4
- 229940116226 behenic acid Drugs 0.000 claims description 4
- 239000004203 carnauba wax Substances 0.000 claims description 4
- 235000013869 carnauba wax Nutrition 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000000344 soap Substances 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 239000007888 film coating Substances 0.000 claims description 2
- 238000009501 film coating Methods 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 27
- 210000004351 coronary vessel Anatomy 0.000 abstract description 9
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000000916 dilatatory effect Effects 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000001020 rhythmical effect Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 17
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 7
- 238000009826 distribution Methods 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 208000006906 Vascular Ring Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 241000212322 Levisticum officinale Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 239000002826 coolant Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000001645 levisticum officinale Substances 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 238000004886 process control Methods 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a chest-relaxing pulse controlled-release dropping pill for enhancing coronary vasodilation, which comprises a pill core, a swelling layer coating and a controlled-release layer coating, wherein the swelling layer coating and the controlled-release layer coating are used for wrapping the pill core, the pill core is a dropping pill prepared by mixing a medicinal material extract and medicinal material micro powder and then mixing the mixture with a dropping pill substrate, the medicinal material extract is a combination of a safflower extract and a ligusticum wallichii extract, and the medicinal material micro powder is a combination of micro powder of pseudo-ginseng, safflower and ligusticum wallichii. The invention also discloses a preparation method of the chest-relaxing pulse controlled-release dropping pill. The chest-relaxing pulse controlled-release dropping pill provided by the invention is a compound traditional Chinese medicine pulse controlled-release dropping pill which accords with chronopharmacology and chronopharmacokinetics and can increase the effect of treating rhythmic diseases such as angina pectoris and the like on dilating coronary vessels at night.
Description
Technical Field
The invention relates to a controlled-release dropping pill, in particular to a chest-relaxing pulse controlled-release dropping pill for enhancing the dilating effect of coronary vessels. The invention also relates to a preparation method of the controlled-release dropping pill.
Background
Angina pectoris is a common and frequently encountered clinical disease. Absolute or relative insufficiency of the blood supply to the myocardium is the main cause of the induced disease, and when angina pectoris attacks, the hardened coronary artery narrows or occludes the lumen of the blood vessel, resulting in acute or temporary ischemia and hypoxia of the myocardium, eventually manifested as chest pain or chest discomfort. Thus, increasing myocardial blood (blood oxygen) supply, such as enhancing coronary vasodilation, can alleviate or eliminate myocardial infarction.
Angina pectoris has circadian rhythm, and if the chest-relaxing drop pill is taken at proper time, the effects of dilating coronary blood vessel, increasing coronary blood flow and resisting platelet can be achieved, but if the disease attacks at night, the blood concentration for effectively dilating coronary blood vessel can not be rapidly generated at the attack time by conventional administration, so that the disease development can be controlled. The pulse administration system is an administration technology developed on the basis of chronopharmacology and chronopharmacokinetics, and has unique advantages in treating rhythmic diseases. Although the pulse drug release system theory of chemical drugs has been developed greatly, the pulse preparation prepared by repeatedly and multi-step extraction of compound traditional Chinese medicines is difficult to timely and effectively play a role according to routine prediction under the action of complex components such as enzyme, gastrointestinal fluid and the like in vivo, and the timing drug release advantage of the pulse drug release system is difficult to play, which is also a technical problem troubling technicians in the field.
Disclosure of Invention
The present invention aims at providing a chest-relaxing pulse controlled-release dropping pill for enhancing the dilation effect of coronary vessels. The chest-relaxing pulse controlled release dropping pill can effectively control the pulse drug release time, enables the drug to start releasing at a preset time and to take effect quickly, is beneficial to expanding coronary vessels, overcomes the defect of insufficient coronary vessel expansion at a preset time of the existing chest-relaxing tablet, chest-relaxing capsule, chest-relaxing dropping pill and other preparations, reduces the administration times, reduces the toxic and side effects, and can greatly increase the compliance of patients.
The invention also aims to provide a preparation method of the chest-relaxing pulse controlled-release dropping pill.
In order to realize the first purpose, the invention adopts the technical scheme that: a chest-relaxing pulse controlled-release dropping pill for enhancing coronary vasodilation comprises a pill core, a swelling layer coating and a controlled-release layer coating, wherein the swelling layer coating and the controlled-release layer coating wrap the pill core, the pill core is a dropping pill prepared by mixing a medicinal material extract and medicinal material micro powder and then mixing the mixture with a dropping pill substrate, the medicinal material extract is a combination of a safflower extract and a ligusticum wallichii extract, and the medicinal material micro powder is a combination of micro powder of pseudo-ginseng, safflower and ligusticum wallichii.
The mass ratio of the medicinal material extract to the medicinal material micro powder is 1: 0.3-1.5.
In the invention, the total mass ratio of the pseudo-ginseng, the safflower and the ligusticum wallichii is 1:1: 2.
The particle size of the medicinal micro powder is within the range of 5-15 mu m. Preferably, the medicinal micro powder is prepared by airflow crushing of pseudo-ginseng, safflower and ligusticum wallichii, the air pressure is 0.35-0.85 Mpa, and the air flow is 10-30 m3Min, and the feeding amount is 1.2-8 kg/h.
The medicinal material extract is a thick extract prepared by extracting safflower and ligusticum wallichii by adopting a conventional decoction method, and the water content of the thick extract is between 15 and 25 percent.
The dripping pill matrix is one or more of PEG, soap, sodium stearate, glycerogelatin, stearic acid and glyceryl monostearate. The mass ratio of the dripping pill substrate to the mixture of the medicinal material extract and the medicinal material micro powder is 1: 0.5-1.25.
The weight increase of the swelling layer coating is 15-25%. The swelling layer coating raw material is one or the combination of more than two of carboxymethyl cellulose (HPMC), ethyl cellulose, acrylic resin, sodium carboxymethyl cellulose, sodium carboxymethyl starch and low-substituted hydroxypropyl methylcellulose.
The weight of the coating of the controlled release layer is increased by 5 to 8 percent. The raw material of the controlled release layer coating is one or the combination of more than two of waxy materials and cellulose hydrophilic gel materials.
The waxy material includes, but is not limited to, one or a combination of two of carnauba wax, beeswax, hydrogenated castor oil, and behenic acid.
The cellulose hydrophilic gel material comprises one or more of but not limited to ethyl cellulose water dispersion, polyethylene oxide and sodium alginate.
In order to achieve the second purpose, the invention adopts the following technical scheme: the preparation method of the chest-relaxing pulse controlled-release dropping pill is characterized by comprising the following steps of:
step 1: respectively pulverizing Notoginseng radix, Carthami flos and rhizoma Ligustici Chuanxiong to obtain Notoginseng radix micropowder, Carthami flos coarse powder, Carthami flos micropowder, rhizoma Ligustici Chuanxiong coarse powder and rhizoma Ligustici Chuanxiong micropowder;
step 2: decocting rhizoma Ligustici Chuanxiong coarse powder with water for 1 hr, filtering, collecting decoction, decocting the residue and Carthami flos coarse powder with water twice, each for 1 hr, filtering, mixing decoctions, filtering, standing the filtrate overnight, collecting supernatant, filtering, concentrating the filtrate to obtain soft extract, adding Notoginseng radix, Carthami flos and rhizoma Ligustici Chuanxiong micropowder, and mixing to obtain mixture;
and step 3: adding drop pill matrix into the mixture, heating and mixing, and making into drop pill to obtain pill core;
and 4, step 4: and sequentially carrying out film coating on the swelling layer and the controlled release layer on the pill core to obtain the chest-relaxing pulse controlled release dropping pill.
In practical application, the selection of the crushing mode plays a decisive role in the exertion of the drug effect of the medicinal materials. The temperature and the drug effect are closely related in the crushing process, and the higher the temperature is, the more unstable the heat and the more difficult the volatile substances in the formula are to be preserved. In the actual operation process, the effective active ingredients in the prescription can be guaranteed to the maximum extent by controlling a reasonable crushing method. Therefore, the invention adopts the airflow to crush the pseudo-ginseng, the safflower and the ligusticum wallichii to obtain the corresponding medicinal material micro powder, thereby avoiding the friction heating phenomenon generated in the crushing process of the grinding medium in the vibration crushing and the mechanical impact crushing and keeping the inherent quality of the medicine unchanged. In the step 1, the pseudo-ginseng is pulverized into micro powder with 90% of particle size aggregate value of 5-15 microns by air flow. The safflower and the ligusticum wallichii are uniformly divided into two parts to be crushed, wherein one part is crushed into coarse powder with the granularity of less than 0.5mm, and the safflower coarse powder and the ligusticum wallichii coarse powder are obtained; the other part is crushed into micro powder with 90 percent of particle size cumulative value of 5-15 mu m to obtain safflower micro powder and ligusticum wallichii micro powder.
The ligusticum wallichii is divided into two parts according to the ratio of 2-4:1, the large part is ground into coarse powder by a conventional grinding method, and the small part is ground into micro powder with 90 percent of particle size aggregate value of 5-15 mu m by air flow.
The safflower is divided into two parts according to the ratio of 1-2:1, the part with large amount is crushed into coarse powder by a conventional crushing method, and the part with small amount is crushed into micro powder with 90 percent of particle size aggregate value of 5-15 mu m by airflow.
In the jet milling, the compressed air pressure and the speed of jetting into the milling cavity are closely related, and the higher the air pressure is, the more concentrated the particle size distribution of the materials which are repeatedly collided, rubbed and sheared at the air flow intersection point. In the actual operation process, reasonable air pressure is controlled to enable the materials to be sprayed into the crushing cavity at a stable speed, and the situation that the materials are intersected with high-pressure air flow due to overhigh pressure is avoidedToo short a time. Therefore, in the step 1, the air pressure of each medicinal material is 0.35-0.85 Mpa, and the air flow is 10-30 m3And/min, carrying out multistage airflow crushing with the feeding amount of 1.2-8 kg/h, and carrying out crushing and screening for classification to obtain the medicinal material micro powder. Preferably, in the air flow crushing in the step 1, the air pressure is 0.4-0.6 Mpa, and the air flow is 15-20 m3Min, and the feeding amount is 2-4 kg/h.
In the step 2, the mass ratio of the medicinal material extract to the medicinal material micro powder is 1: 0.3-1.5. Preferably, the mass ratio of the medicinal material extract to the medicinal material micro powder is 1: 0.5-1.1.
In step 3, the dripping pill matrix is one or the combination of more than two of PEG, soap, sodium stearate, glycerogelatin, stearic acid and glyceryl monostearate. The mass ratio of the dripping pill substrate to the mixture of the medicinal material extract and the medicinal material micro powder is 1: 0.5-1.25.
In the step 4, the weight increase of the swelling layer coating is 15-25%. The swelling layer coating raw material is one or the combination of more than two of carboxymethyl cellulose (HPMC), ethyl cellulose, acrylic resin, sodium carboxymethyl cellulose, sodium carboxymethyl starch and low-substituted hydroxypropyl methylcellulose.
In step 4, the weight of the coating of the controlled release layer is increased by 5 to 8 percent. The raw material of the controlled release layer coating comprises one or the combination of more than two of waxy materials and cellulose hydrophilic gel materials. The waxy material includes, but is not limited to, one or a combination of two of carnauba wax, beeswax, hydrogenated castor oil, and behenic acid. The cellulose hydrophilic gel material comprises one or more of but not limited to ethyl cellulose water dispersion, polyethylene oxide and sodium alginate.
The invention has the beneficial effects that:
1. the chest-relaxing pulse controlled-release dropping pill provided by the invention is a coating film controlled pulse preparation, is beneficial to providing effective blood concentration of the medicine in a preset time, and can achieve the purpose of selective treatment of angina pectoris in the early morning. Can promote the effective components to play, thereby achieving the aim of safely and effectively treating the angina. Therefore, compared with the traditional chest-relaxing dropping pill, the chest-relaxing pulse controlled release dropping pill provided by the invention can be rapidly disintegrated and released in a preset time, keeps the effective medicine concentration, has an obvious effect of dilating coronary vessels, and is possible to apply a pulse medicine release system in a traditional Chinese medicine preparation.
2. The chest-relaxing pulse controlled-release dropping pill provided by the invention is prepared by combining medicinal material micro powder and medicinal material extract, and can achieve the effects of timed pulse drug release and time-selecting effect. The medicinal materials are pulverized by airflow and then are not subjected to extraction, decoction and other treatments, so that the loss of effective components in the production link is avoided, the pulverization process does not generate an overheating phenomenon, the pulverization speed is high, and the retention of the biological active components which cannot resist high temperature is facilitated.
3. The invention adopts medicinal material micro powder particles obtained by jet milling, and the average particle size of the particles is less than 10 mu m and the cumulative value of 90 percent of the particle size is less than or equal to 8 mu m by adopting a laser particle size method. The specific surface area, the adsorbability, the solubility and the like of the medicinal materials are correspondingly increased.
4. The chest relaxing formula consists of three medicinal materials of pseudo-ginseng, ligusticum wallichii and safflower, wherein the pseudo-ginseng has the functions of promoting blood circulation, removing blood stasis and relieving pain, the safflower has the functions of promoting blood circulation, removing blood stasis and relieving pain, and the ligusticum wallichii is used for assisting in promoting qi circulation, promoting blood circulation, removing blood stasis and relieving pain. The three medicines are combined together to play the roles of activating blood circulation, removing blood stasis and relieving pain. Notoginseng radix is rich in Notoginseng radix saponin, Notoginseng radix polysaccharide, dencichine, and flavone effective components, and has effects of stopping bleeding, promoting blood circulation for removing blood stasis, relieving swelling and pain, nourishing and strengthening body, relieving fatigue, resisting anoxia, resisting aging, reducing blood lipid, lowering blood pressure, and improving immunity. The three medicinal materials can generate different effects by different processing methods, raw panax notoginseng whole powder has good effect when being used as a medicine in cardiovascular and cerebrovascular diseases such as coronary heart disease, hyperlipidemia, hypertension and the like, the extracts and the micro powder of the safflower and the ligusticum wallichii have the effect of increasing coronary blood flow and myocardial nutritional blood flow, and the micro powder can retain the effect of promoting blood circulation and is beneficial to effectively playing the effect of activating qi in the medicinal materials.
Drawings
FIG. 1 is a particle size distribution diagram of example 1;
FIG. 2 is a particle size distribution diagram of example 2;
FIG. 3 is a particle size distribution diagram of example 3;
figure 4 is a graph of the cumulative percent drug released at each time point for examples 1-3.
Detailed Description
The technical solution of the present invention will be described in further detail with reference to the following embodiments, but the present invention is not limited thereto.
Example 1
Pulverizing Notoginseng radix, Carthami flos and rhizoma Ligustici Chuanxiong into coarse powder with particle size below 1.5mm by universal pulverizing method, respectively, and air pressure of 0.4Mpa and air flow of 18m3Min, the feeding amount is 2.5kg/h, and the micro powder with the particle size of 90 percent and the accumulated value of the particle size of about 8 mu m is obtained by crushing, screening and grading. Taking 750g of coarse powder of the ligusticum wallichii, adding water, decocting for 1 hour, filtering and keeping a decoction for later use; decocting the dregs and 250g of safflower coarse powder in water twice, each time for 1 hour, combining the three decoctions, filtering, standing the filtrate overnight, taking the supernatant, filtering, concentrating the filtrate until the water content of the thick paste is 20 percent, the weight is 185-210 g, adding 250g of safflower and ligusticum wallichii micro powder and 500g of pseudo-ginseng micro powder respectively, mixing with dripping pill matrix PEG4000800g, heating and mixing, preparing dripping pill core with vegetable oil as condensing agent, removing surface coolant, making into pill, coating with fluidized bed, taking a mixed aqueous solution containing 12g/l of carboxymethyl cellulose (HPMC) and 18g/l of sodium carboxymethyl cellulose as a swelling layer coating solution to carry out swelling layer coating so as to increase the weight of the pill core by about 15.5 percent, taking 25g/l of ethyl cellulose aqueous dispersion coating solution as a controlled release layer coating so as to increase the weight of the pill core by about 5.7 percent, and obtaining the chest-soothing pulse controlled release dropping pill after coating and curing.
Example 2
Taking three medicinal materials of pseudo-ginseng, safflower and szechuan lovage rhizome, adopting TongPulverizing into coarse powder with particle size below 1.8mm by universal pulverizing method, and air pressure of 0.55Mpa and air flow of 20m3Min, 2kg/h of feeding amount, and grinding, screening and grading to obtain the micro powder with 90% of particle size accumulation value of about 8 mu m. Taking 750g of coarse powder of the ligusticum wallichii, adding water, decocting for 1 hour, filtering and keeping a decoction for later use; decocting the medicine residues and 250g of safflower coarse powder twice with water, each time lasting for 1 hour, combining three decoctions, filtering, standing the filtrate overnight, taking supernatant, filtering, concentrating the filtrate until the water content of thick paste is 22%, the weight is 185-210 g, adding 250g of each safflower and ligusticum wallichii micro powder, 500g of pseudo-ginseng micro powder, PEG4000300g serving as a dropping pill matrix, a proper amount of stearic acid and paraffin, heating and uniformly mixing, taking liquid paraffin as a condensing agent to prepare a dropping pill core, removing a cooling agent on the surface, performing pill preparation, then adopting a fluidized bed coating method, taking a mixed aqueous solution containing 12g/l of HPMC and 18g/l of sodium carboxymethyl cellulose as a coating solution to perform coating so as to enable the weight of the pill core to be about 21.0%, taking 25g/l of ethyl cellulose aqueous dispersion coating solution as a controlled release layer to coat the pill core so as to enable the weight to be about 7.0%, and obtaining the chest-relaxing pulse controlled release.
Example 3
Pulverizing Notoginseng radix, Carthami flos and rhizoma Ligustici Chuanxiong into coarse powder with particle size below 2.0mm by universal pulverizing method, respectively, and air pressure of 0.4Mpa and air flow of 15m3Min, 4kg/h of feeding amount, and grinding, screening and grading to obtain the micro powder with 90% of particle size accumulation value of about 10 mu m. Taking 750g of coarse powder of the ligusticum wallichii, adding water, decocting for 1 hour, filtering and keeping a decoction for later use; decocting the medicine residues and 250g of safflower coarse powder in water twice, each time lasting 1 hour, combining three decoctions, filtering, standing the filtrate overnight, taking supernatant, filtering, concentrating the filtrate until the water content of the thick paste is 18%, the weight is 185-210 g, adding 250g of safflower micro powder and 250g of ligusticum wallichii micro powder respectively, 500g of pseudo-ginseng micro powder, heating and mixing the mixture with a dripping pill matrix PEG4000400g, a proper amount of stearic acid and paraffin, preparing a dripping pill core by using liquid paraffin as a condensing agent, removing a cooling agent on the surface, performing pill preparation, and coating by using a fluidized bed coating method by using a mixed aqueous solution containing 12g/l of HPMC and 18g/l of sodium carboxymethyl cellulose as a coating solution to coat the pill core so as to enable the pill core to be coatedThe weight is increased by about 23.0 percent, 25g/l of ethyl cellulose aqueous dispersion coating liquid is taken as a controlled release layer coating to increase the weight of the pill core by about 7.5 percent, and the chest-relaxing pulse controlled release dropping pill is obtained after coating and curing.
In order to illustrate the preparation characteristics, the delayed release and the coronary vasodilation enhancing property of the chest-relaxing pulse controlled release dropping pill. The examples are illustrated by increasing the comparison of the pulsed controlled release dripping pills prepared by conventional extraction processes in the following experiments. The pulse controlled release dropping pill (process control group) prepared by the traditional extraction process is different from the chest-relaxing pulse controlled release dropping pill in the invention in preparation method, namely, the traditional process is that three medicinal materials of pseudo-ginseng, szechuan lovage rhizome and safflower are taken and crushed into coarse powder, the pseudo-ginseng and the szechuan lovage rhizome are decocted for 2 hours by adding water, and the filtration is carried out, and the filtrate is reserved; decocting the residues and safflower in water for 2 times, each time for 1 hour, combining the decoctions for 3 times, filtering, standing the filtrate for 24 hours to obtain an extract, and mixing the extract with a substrate to prepare dripping pills, coatings and the like, which are the same as other steps in the invention.
1. Particle size
Test drugs: safflower micro powder, Ligusticum wallichii micro powder and notoginseng micro powder;
the experimental method comprises the following steps:
taking safflower micro powder, rhizoma ligustici wallichii micro powder and pseudo-ginseng micro powder, measuring by using an Euramerican style LS-C particle size analyzer, selecting a dry method sample injector, taking a dispersion medium as air, measuring the particle size distribution, wherein the particle size distribution diagram of the embodiment 1-3 is shown in a figure 1-3, and the 90% particle size accumulated value is shown in a table-1.
The 90% particle diameter integrated value (D90) of examples 1 to 3 is shown in Table-1:
TABLE-1 90% cumulative particle size value (D90) for examples 1-3
| Item | Example 1 | Example 2 | Example 3 |
| D90 | 7.58±0.15 | 8.08±0.27 | 9.97±0.33 |
2. In vitro Release evaluation
Test drugs: the chest-relaxing pulsed controlled-release dropping pill of example 1-3;
the experimental method comprises the following steps: the release rate is determined by adopting a device of a third method (small cup method) of dissolution and release rate determination method 0931 in appendix of the second part of Chinese pharmacopoeia 2015 edition, wherein the dissolution medium (0.1mol/L hydrochloric acid solution, pH6.8 phosphate buffer) is 250ml, the temperature (37 +/-0.5) DEG C and the rotating speed is 50 rpm. The measurement was carried out in 0.1mol/L hydrochloric acid solution for the first 2 hours, and the measurement was continued in a phosphate buffer solution of pH6.8 after 2 hours, and 5mL of the solution was sampled at predetermined time intervals. The cumulative percent drug released at each time point was determined.
The experimental results are as follows: as can be seen from the release rate test results in Table 2 and the release profile in FIG. 4, ideal release lag time and pulse release time can be achieved by adjusting the coating formulations of the swelling layer and the controlled release layer.
TABLE-2 cumulative percent drug release (%) -at each time point of examples 1-3
| Time/h | Example 1 | Example 2 | Example 3 |
| 1 | 0％ | 0％ | 0％ |
| 2 | 0％ | 0.11％ | 0％ |
| 3 | 5.1％ | 8.46％ | 3.17％ |
| 4 | 10.39％ | 15.49％ | 8.25％ |
| 6 | 70.11％ | 70.88％ | 66.91％ |
| 8 | 88.9％ | 84.17％ | 80.08％ |
| 10 | 91.45％ | 90.36％ | 86.42％ |
| 12 | 97.61％ | 99.12％ | 92.57％ |
3. Effect on isolated vascular ring tone
Test drugs: the chest-relaxing pulse controlled-release dropping pill of the embodiment 1-3 and the chest-relaxing capsule contrast group and the process contrast group sold in the market release the dissolution medium for 12 hours in vitro, and the administration concentration is 0.1g/ml (calculated by the raw medicinal materials) each time;
the experimental method comprises the following steps:
the evaluation method comprises the following steps: the Wistar rat is killed by cutting off the head, the chest is cut off, the blood vessel of the thoracic aorta is quickly taken out, the blood vessel can not be pulled forcefully in the process, the taken-out blood vessel is put into Krebs nutrient solution of ice bath, the redundant hoof tissue on the blood vessel is removed by scissors, and then the blood vessel is cut into a blood vessel ring with the diameter of about 3mm by the scissors. After the vascular ring is prepared, the vascular ring is hung in a 5ml bath tank which is previously put with Krebs nutrient solution, the bath tank temperature is set to 37 ℃, and 95 percent O is continuously supplied to the bath tank2And 5% CO2The tension transducer was connected to record the change in tension of the vascular ring, the expansion force of 1g loading before administration, 2ml of test drug was started after 20min of equilibration, and the change in aortic tension was recorded.
The experimental results are as follows: the results of the pre-administration and post-administration preload aortic vessel tension in different examples are shown in Table-3, and the chest-relaxing pulse controlled-release dropping pill disclosed by the invention can effectively increase the coronary vessel dilatation.
TABLE-3 Effect of different art chest-relaxing preparations on isolated vascular ring tension in rats
| Before administration (g) | After administration (g) | Percent reduction in tension | |
| Blank space | 6.4±1.10 | 6.6±1.07 | - |
| Process control group | 6.3±0.92 | 5.8±1.12 | 7.94％ |
| Commercially available capsules | 6.5±1.26 | 6.1±1.34 | 5.48％ |
| Example 1 | 6.2±1.04 | 3.7±0.98 | 79.31％ |
| Example 2 | 6.9±0.85 | 2.3±0.92 | 57.82％ |
| Example 3 | 6.1±1.49 | 3.8±1.50 | 81.87％ |
4. Influence on isolated cardiac coronary flow of rat
Test drugs: examples 1-3 chest-relaxing pulsed controlled-release dropping pills, a contrast group of commercially available chest-relaxing capsules and a process contrast group, wherein the administration concentration is 0.1 g/ml;
the evaluation method comprises the following steps: the Wistar rat is killed by cutting off the head, the chest is cut, the heart is taken out quickly, the heart is placed in a culture dish containing 4 ℃ H-K liquid, the aorta cannula is immediately inserted into the aorta, the aorta is tied and fixed by a thread, the heart is slightly squeezed by hands, residual blood in the heart is emptied, meanwhile, the attached pericardium and lung tissue are removed, the H-K liquid is reversely perfused into the myocardium at 37 ℃, the perfusate flows into the right atrium from the coronary artery by blood, the heart adapts for 5min, after the flow is stable, the coronary flow per minute is continuously measured for 3 times, the average value of the 3 times of flow is used as the normal flow before administration, then H-K liquid containing different test sample liquid medicines is accessed, the coronary flow for 5min is respectively recorded, and data are recorded.
The experimental results are as follows:
the results of the coronary flow of the heart before and after the administration in different embodiments are shown in Table-4, and the adoption of the chest-relaxing pulse controlled-release dropping pill disclosed by the invention can effectively increase the coronary flow.
TABLE-4 Effect of different technological chest-relaxing preparations on coronary flow of rat heart
| Before medicine (ml) | After administration (ml) | Coronary flow (%) | |
| Blank space | 7.1±0.16 | 6.94±0.23 | - |
| Commercially available capsules | 6.82±0.48 | 7.68±0.61 | 12.61％ |
| Process control group | 6.63±0.54 | 7.71±0.90 | 16.29％ |
| Example 1 | 5.96±0.39 | 8.03±0.49 | 34.73％ |
| Example 2 | 6.34±0.97 | 8.49±0.57 | 33.91％ |
| Example 3 | 6.02±0.74 | 8.24±0.39 | 36.88％ |
The above description is only exemplary of the invention, and any modification, equivalent replacement, and improvement made within the spirit and scope of the present invention should be considered within the scope of the present invention.
Claims (9)
1. A chest-relaxing pulse controlled-release dripping pill for improving coronary vasodilation effect is characterized by comprising a pill core, a swelling layer coating for coating the pill core anda controlled release layer coating, wherein the pill core is a dropping pill prepared by mixing a medicinal material extract and medicinal material micro powder and then mixing the mixture with a dropping pill substrate, wherein the medicinal material extract is the combination of a safflower extract and a ligusticum wallichii extract, and the medicinal material micro powder is the combination of the micro powder of the pseudo-ginseng, the safflower and the ligusticum wallichii; the medicinal micro powder is prepared by crushing pseudo-ginseng, safflower and ligusticum wallichii through air flow, wherein the air pressure is 0.35-0.85 Mpa, and the air flow is 10-30 m3Min, and the feeding amount is 1.2-8 kg/h.
2. The chest-relaxing pulse controlled-release dropping pill for enhancing coronary vasodilation according to claim 1, wherein the mass ratio of the medicinal material extract to the medicinal material micro powder is 1: 0.3-1.5.
3. The chest-relaxing pulse controlled-release dropping pill for enhancing coronary vasodilation as claimed in claim 1, wherein the particle size of the medicinal material micro powder is within the range of 5-15 μm.
4. The chest-relaxing pulse controlled-release dropping pill for enhancing coronary vasodilation according to claim 1, wherein the medicinal material extract is a thick extract prepared by extracting safflower and ligusticum wallichii by a conventional decoction method, and the water content of the thick extract is between 15% and 25%.
5. The chest-relaxing pulse controlled-release dropping pill for enhancing coronary vasodilation according to claim 1, wherein the dropping pill matrix is one or a combination of more than two of PEG, soap, sodium stearate, glycerogelatin, stearic acid and glyceryl monostearate, and the mass ratio of the dropping pill matrix to the mixture of the medicinal material extract and the medicinal material micro powder is 1: 0.5-1.25; the weight of the swelling layer coating is increased by 15-25%, and the swelling layer coating is prepared from one or more than two of carboxymethyl cellulose, ethyl cellulose, acrylic resin, sodium carboxymethyl cellulose, sodium carboxymethyl starch and low-substituted hydroxypropyl methylcellulose; the weight of the controlled release layer coating is increased by 5-8%, and the controlled release layer coating is prepared from one or more than two of waxy materials and cellulose hydrophilic gel materials; the waxy material comprises one or a combination of two of carnauba wax, beeswax, hydrogenated castor oil and behenic acid; the cellulose hydrophilic gel material comprises one or the combination of more than two of ethyl cellulose water dispersion, polyethylene oxide and sodium alginate.
6. The method for preparing the chest-relaxing pulsed controlled release dropping pill of any one of claims 1 to 5, which is characterized by comprising the following steps:
step 1: respectively pulverizing Notoginseng radix, Carthami flos and rhizoma Ligustici Chuanxiong to obtain Notoginseng radix micropowder, Carthami flos coarse powder, Carthami flos micropowder, rhizoma Ligustici Chuanxiong coarse powder and rhizoma Ligustici Chuanxiong micropowder;
step 2: decocting rhizoma Ligustici Chuanxiong coarse powder with water for 1 hr, filtering, collecting decoction, decocting the residue and Carthami flos coarse powder with water twice, each for 1 hr, filtering, mixing decoctions, filtering, standing the filtrate overnight, collecting supernatant, filtering, concentrating the filtrate to obtain soft extract, adding Notoginseng radix, Carthami flos and rhizoma Ligustici Chuanxiong micropowder, and mixing to obtain mixture;
and step 3: adding drop pill matrix into the mixture, heating and mixing, and making into drop pill to obtain pill core;
and 4, step 4: and sequentially carrying out film coating on the swelling layer and the controlled release layer on the pill core to obtain the chest-relaxing pulse controlled release dropping pill.
7. The method for preparing the chest-relaxing pulse controlled-release dropping pill as claimed in claim 6, wherein in the step 1, the notoginseng is pulverized into micro powder with 90% particle size cumulative value of 5-15 μm by air flow; the safflower and the ligusticum wallichii are uniformly divided into two parts to be crushed, wherein one part is crushed into coarse powder with the granularity of less than 0.5mm, and the safflower coarse powder and the ligusticum wallichii coarse powder are obtained; the other part is crushed into micro powder with 90 percent of particle size cumulative value of 5-15 mu m to obtain safflower micro powder and ligusticum wallichii micro powder.
8. The preparation method of the chest-relaxing pulse controlled-release dropping pill as claimed in claim 7, wherein the rhizoma Chuanxiong is divided into two parts according to a ratio of 2-4:1, the more part is pulverized into coarse powder by a conventional pulverizing method, and the less part is pulverized into fine powder with 90% particle size aggregate value of 5-15 μm by air flow; the safflower is divided into two parts according to the ratio of 1-2:1, the part with large amount is crushed into coarse powder by a conventional crushing method, and the part with small amount is crushed into micro powder with 90 percent of particle size aggregate value of 5-15 mu m by airflow.
9. The method for preparing the chest-relaxing pulsed controlled-release dropping pill according to claim 7, wherein in the step 1, the air pressure of each medicinal material is 0.35-0.85 Mpa, and the air flow is 10-30 m3The feed amount is 1.2-8 kg/h, and the medicinal material micro powder is obtained by crushing and screening; in the step 2, the mass ratio of the medicinal material extract to the medicinal material micro powder is 1: 0.3-1.5; in the step 3, the mass ratio of the dripping pill substrate to the mixture of the medicinal material extract and the medicinal material micro powder is 1: 0.5-1.25, and the dripping pill substrate is one or a combination of more than two of PEG, soap, sodium stearate, glycerogelatin, stearic acid and glyceryl monostearate; in the step 4, the weight of the swelling layer coating is increased by 15-25%, and the swelling layer coating is prepared from one or more of carboxymethyl cellulose, ethyl cellulose, acrylic resin, sodium carboxymethyl cellulose, sodium carboxymethyl starch and low-substituted hypromellose; in the step 4, the weight of the controlled release layer coating is increased by 5 to 8 percent, and the controlled release layer coating raw material comprises one or the combination of more than two of waxy materials and cellulose hydrophilic gel materials; the waxy material comprises one or the combination of two of carnauba wax, beeswax, hydrogenated castor oil and behenic acid, and the cellulose hydrophilic gel material comprises one or the combination of two of ethyl cellulose water dispersion, polyethylene oxide and sodium alginate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711147105.XA CN107669727B (en) | 2017-11-17 | 2017-11-17 | Chest-relaxing pulse controlled-release dropping pill for enhancing coronary vasodilation effect of chest-relaxing dropping pill and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711147105.XA CN107669727B (en) | 2017-11-17 | 2017-11-17 | Chest-relaxing pulse controlled-release dropping pill for enhancing coronary vasodilation effect of chest-relaxing dropping pill and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107669727A CN107669727A (en) | 2018-02-09 |
| CN107669727B true CN107669727B (en) | 2020-08-14 |
Family
ID=61150001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711147105.XA Active CN107669727B (en) | 2017-11-17 | 2017-11-17 | Chest-relaxing pulse controlled-release dropping pill for enhancing coronary vasodilation effect of chest-relaxing dropping pill and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107669727B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103638085A (en) * | 2013-11-05 | 2014-03-19 | 广东药学院 | Thorax-comforting pulse controlled-release dropping pill and preparation method thereof |
-
2017
- 2017-11-17 CN CN201711147105.XA patent/CN107669727B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107669727A (en) | 2018-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02006473A (en) | Odormasking coating for a pharmaceutical preparation. | |
| CN104825791B (en) | A kind of traditional Chinese medicine health care product with anti-fatigue effect and preparation method thereof | |
| CN107137376A (en) | A kind of black fruit fructus lycii extract microcapsule and wolfberry formulation prepared therefrom | |
| US11013694B2 (en) | Formulation of a micro drop pill and the preparation method thereof | |
| JP2021031488A (en) | Pellet formulation containing single or complex herbal extract at high concentration and manufacturing method therefor | |
| CN1171623C (en) | Prepn of medicine for treating hepatosis | |
| CN102085344B (en) | Aplotaxis carminative sustained-release preparation and preparation method thereof | |
| CN107669727B (en) | Chest-relaxing pulse controlled-release dropping pill for enhancing coronary vasodilation effect of chest-relaxing dropping pill and preparation method thereof | |
| CN102125662B (en) | Compound traditional Chinese medicine for treating apoplexia and preparation method and application thereof | |
| CN103271978A (en) | Ginkgo leaf compound preparation for resisting oxygen deprivation and glucose deprivation and treating altitude sickness | |
| WO2005049058A1 (en) | Radix salviae miltiorrhizae, extract and composition thereof for the treatment of the aspirin resistance diseases | |
| CN1872232B (en) | Composition of medication for curing cerebrovascular disease, and preparation method | |
| CN1977944A (en) | Red ginseng and lilyturf root soft capsule and its preparing method | |
| CN1631395A (en) | Gingko leaf sustained release formulation and preparation process thereof | |
| CN102895627A (en) | Preparation technology and production method for integrated new formulation of radix bupleuri, cassia twig and dry ginger decoction | |
| CN105726921A (en) | Traditional Chinese medicine composition and preparation for treating deficiency of both qi and blood | |
| CN100453073C (en) | Compound radical lobelia dripping pill and its preparing method | |
| CN104367908B (en) | It is a kind of to treat pharmaceutical composition of angiocardiopathy and its production and use | |
| CN1872230B (en) | A medication for treating coronary heart disease and preparation method | |
| CN110522772B (en) | Ginkgo leaf composition and preparation method thereof | |
| CN100571697C (en) | A kind of drop pills of seabuckthorn fruit flavone | |
| CN102100769A (en) | Preparation technique for ephedra and bighead atractylodes rhizome decoction in novel formed formulation and production method thereof | |
| CN100348178C (en) | 'Ganjing' dripping pills for treating liver disease and its preparation | |
| CN1813886B (en) | Chinese medicine formulation for activating blood flow and removing blood stasis and stopping pain, and its preparing method | |
| CN1745791B (en) | Use of medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |